NICE wants more data for lung cancer treatment Iressa
29 January 2010
Francesca Bruce
NICE, the health technology appraisal body for England and Wales, has asked
AstraZeneca for more information about its Iressa (gefitinib) for treating non-small-cell lung cancer (NSCLC). Meanwhile, the firm's submission to NICE marks a first for patient access schemes.
The institute's appraisal...
Please Login to read the full article.
29 January 2010
Francesca Bruce
The institute's appraisal...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Scotland says yes to BI/Lilly's Tradjenta and Lilly's Bydureon
- Easing of Japanese Tarceva restrictions in NSCLC set to raise pressure on Iressa
- NICE no for Tyverb and Herceptin in breast cancer, Roche considers appeal
- Roche pins Tarceva hope on Cancer Drugs Fund after NICE rejects appeal
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
